and timely production of vaccines in the event of a pandemic influenza outbreak would be challenging. Currently, antivirals used for prophylactic and therapeutic treatment of influenza infection target either the neuraminidase or the M2 ion channel protein. [3] [4] [5] There continues to be a need for novel, more efficacious drugs due to drug resistance by seasonal influenza viruses 6 as well as emerging potential pandemic strains H5N1 7 and H7N9 8 .
Influenza virus contains eight negative-stranded RNA genomic segments. The three largest RNA segments encode for the polymerase acidic protein (PA), polymerase basic protein 1 (PB1), and polymerase basic protein 2 (PB2) that assemble to form a heterotrimeric viral RNA-dependent RNA polymerase (RdRP). [9] [10] [11] The influenza RdRP is highly conserved among all influenza strains and subtypes, and is essential for viral transcription and replication. Transcription is initiated by hijacking a 5' cap from the host cell pre-mRNAs via a 'cap snatching' mechanism. 12, 13 This entails the binding of PB2 to the 5'-cap ( m7 G) of the host cell's pre-mRNA, which is then cleaved 10-13 nucleotides downstream by the endonuclease activity of influenza RdRP. 13 The cleaved 5'-capped RNA segment is used as a primer to initiate transcription of the viral mRNA.
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The cap-snatching event is not a normal cellular process; however, it is an essential step in the influenza virus lifecycle. Additionally, recent discovery of an alternative encoded protein, PA-X, which has an overlapping sequence and similar enzymatic activity as PA N , may contribute to the host protein shutdown observed during influenza A infection. 14 Thus, inhibition of the endonuclease activity of influenza RdRP is an attractive target for novel antiviral therapy.
Biochemical and structural studies have elucidated that the endonuclease active site resides in the N-terminal domain of the PA subunit (PA N ). [15] [16] [17] Crystal structures of H5N1 16 and H3N2 17 PA N revealed the architecture of the enzymatic domain. The domain fold and active site arrangement of PA N were found to be similar to those of the PD-(D/E)XK family of nucleases. Mutagenesis of catalytic residues within the RdRP showed that endonuclease-dependent transcription was abolished while the endonucleaseindependent RNA replication was maintained. 16 Endonuclease activity of PA N was further validated by the hydrolysis of both single-stranded RNA and single-stranded DNA substrates. tetramic acids, 24 and the green tea catechins, 25, 26 were identified through pharmacological screening.
However, lack of critical information regarding the location of the endonuclease site and its structure did not permit pursuit of structure-based drug design (SBDD). Structures of PA N have revealed a deep active site cleft containing multiple subpockets that can be exploited for drug design
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( Figure 1A ). Crystal structures of PA N in complexes with inhibitors have revealed a common chelation mode with the two active site metal ions (M1 and M2) despite extending into different subpockets. 18, 19 The structural characterization of PA N has renewed interest in the development of endonuclease inhibitors. Crystal structures of pH1N1 endonuclease were determined in complexes with nucleotides and known inhibitors. 18 Baughman et al. used a fluorescence polarization assay to establish structure-activity relationships (SAR) for a carboxamide-based series of inhibitors reported to have activity in the micromolar to nanomolar range. 27 Antiviral activity for one of these compounds was determined to be 12.7 µM (see Supplemental Table 1 for antiviral activity comparisons of known influenza endonuclease inhibitors). Crystal structures for a subset of the compounds in complex with H5N1 PA N helped to rationalize the observed potency for the series. 19 Here, we report results from a small molecule fragment screening effort against 2009 pandemic H1N1 (pH1N1) PA N . SBDD for a promising fragment was pursued to develop a series of compounds that demonstrated antiviral activity. The compounds exhibit a mode of chelation to the active site metal ions that is different from the chelating mode observed for typical endonuclease inhibitors, such as diketo acid compounds.
Results and Discussion

Crystal Engineering of PA N for SBDD
The initial crystal forms for influenza endonuclease were not suitable for SBDD due to occlusion of the active site 15 and difficulty of reproducing the crystals. 19 To search
for an appropriate crystal form, the H5N1 endonuclease construct (obtained from 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Table 2 ). This construct could be crystallized in multiple conditions. A condition with PEG 8000 as precipitant in the presence of 5 mM 
Fragment Screening
Fragment screening by X-ray crystallography was conducted using a previously assembled diverse compound library 30 by soaking fragments into preformed crystals.
Although the fragment library was not biased to contain metal chelators, 159 compounds were found to contain potentially chelating moieties. Of the 159 potential metal chelators, eight fragments inhibited PA N (Supplemental Table 3 ). Initial screening of 775 fragments was done using cocktails of four to eight compounds designed to ensure maximum structural diversity and minimum chemical reactivity. 30 Fragment hits Table 4 ). All fragments were also subjected to a secondary screen using a high-throughput fluorescence resonance energy transfer based inhibition assay, 28 analogous to those developed by Kowalinski et al. 17 as well as Noble et al. 31 The measured IC 50 for each compound was then used to calculate the apparent ligand efficiency (LE), which is the binding contribution per non-hydrogen atom (NHA) of a compound. 32, 33 LE, a widely used metric in fragment screening experiments to rank small molecules based on their average affinity contribution per atom, was used as a guide for hit selection and lead optimization.
Third Metal Binding at the Active Site
Of the eight fragments identified during the course of our fragment screening, four fragments chelated to the two catalytic metal ions, M1 and M2, in a mode similar to the known endonuclease inhibitors. Surprisingly, binding of compound 1 revealed the presence of a previously undetected third metal ion (M3) in the active site cleft, at a distance ~4 Å from M2 ( Figure 2A ). Compound 1 binds to two sites: subpocket 2, which consists of Leu16, Lys19, Ala20, Glu23, Gly81, and Asp83, as well as subpocket 3
surrounded by Tyr24, Glu26, Lys34, and Ile38 ( Figure 2A ). The imidazole moieties of both molecules coordinate with M3. The side chain of Glu80 can no longer coordinate with M2 due to steric clash with M3, which is located 1.0 Å from the Glu80 of the apo structure. Coordination to M3 requires the side chain of Glu80 to shift such that the carboxylate rotates 90˚ and no longer coordinates with M2. As a result, weak electron . 34 It is possible that the third metal observed in the active site due to binding of 1 is stabilized by coordination to the substrate. In order to determine if M3 is an artifact of fragment binding, we titrated metals (specifically manganese and calcium) into EDTA-treated crystals of PA N , which was necessary to remove residual metal ions from the crystallization condition. Due to difficulties in determining a crystal structure of PA N in complex with RNA, soaking of high concentrations of various metals into crystals of PA N without substrate present was used to compensate for the lack of substrate coordination to M3. Soaks of magnesium, manganese, zinc, and nickel salts did not give conclusive results due to loss of X-ray diffraction resolution. A calcium soak, however, gave high-resolution X-ray diffraction with clear electron density for the metal ions with their coordinating residues and water molecules.
It was previously determined that calcium thermally stabilized PA N without enhancing endonuclease activity. 17, 35 Surprisingly, a 100 mM calcium soak revealed metal binding at the M2 and M3 sites but not at the M1 site ( Figure 2B ); binding of a
Mg
2+
ion only at the M2 site and not the M1 site was earlier observed in the H5N1 PA N structure. 16 Soaking revealed that the position of M3, 2.5 Å away from Glu80, allowed
Glu80 to coordinate with both M3 and M2, which was not seen in PA N in complex with 1.
Bipyramidal pentavalent coordination with the protein and water molecules confirmed Although this may not necessarily be the case with respect to influenza endonuclease, the presence of the third metal binding near the active site suggests the need for further studies particularly in the presence of ssRNA substrates.
Indeed, a third metal near the active site maybe relevant for other enzymes in the PD-(D/E)XK family of nucleases.
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Hit-to-lead Development
Fragment screening subsequently identified 5-chloro-3-hydroxypyridin-2(1H)-one as an active site chelating ligand in the presence of the third metal. Stronger electron density was observed for a bromine derivative of this initial hit (2). Subsequent refinement of the structure revealed three copies of 2 bound to PA N . Two molecules of 2 were bound to the subpockets 2 and 3 and chelated to M3, analogous to the binding of 1,
while the third molecule of 2 coordinated with M1 and M2 at the endonuclease active site 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 ( Figures 3A-B ). An IC 50 value of 16 µM was determined for 2 using the enzymatic assay.
The ligand efficiency of 0.73 kcal/mol NHA was calculated assuming the inhibition was solely due to binding of the compound to the active site.
Binding of 2 to subpockets 2 and 3 creates an interaction network between the hydroxyls of 2, M3, and a coordinating water molecule. M3 is shifted 1.8 Å from its location in the structure in complex with 1, which allows Glu80 to coordinate with both M2 and M3. A non-optimal hydrophobic interaction network is created upon binding of 2 to subpockets 2 and 3. This network consists of π-stacking interaction between the side chains of Arg84 and Glu23, which, in turn, weakly interacts with the bromine of 2 bound to subpocket 2. The side chains of Ala20 and Tyr24 help bridge the network by participating in weak hydrophobic interactions with 2 bound to both subpockets 2 and 3.
Compound 2 binding to subpocket 3 forms hydrophobic interactions with Lys34 and Ile38. Additionally, the bromine of 2 bound to subpocket 3 forms a halogen bond with a carboxylate oxygen of Glu26 at a distance of 2.9 Å.
Compound 2 bound at the active site also creates an interaction network of its own by coordinating with M1 and M2 and forming a hydrogen bond with Lys134 at a distance of 2.7 Å. The typical binding motif for influenza endonuclease inhibitors entails three chelating groups forming four coordinating interactions with M1 and M2 ( 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60
( Figure 3B ). The pyridinone nitrogen is also within hydrogen-bonding distance (2.8 Å)
from a side-chain oxygen of Glu80. A striking difference between 2 and known three group chelating inhibitors is that the pyridinone ring of 2 is tilted by an angle of ~50˚ towards His41 ( Figure 3B ). This orientation of 2 allows for favorable π-stacking interactions with the aromatic side chain of His41, an invariant metal-chelating residue in PA N of all influenza viruses. Moreover, the distinct binding mode and chelation of 2 at the active site provided opportunities for designing new chemical classes of endonuclease inhibitors, and hit-to-lead optimization was conducted in this case.
Synthetically feasible chemical modifications were designed using structural information and molecular docking of the designed compounds was undertaken using AutoDock Vina. 45 The most promising substitutions/modifications predicted to improve the binding affinity were considered for chemical synthesis. Each of the synthesized pyridinone derivatives was evaluated for endonuclease inhibitory activity using the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 12 inhibition of endonuclease activity. A plausible explanation is that substitutions at the 4-position may perturb the electronic arrangements of the chelating oxygens of the pyridinone ring.
Substitution at the 5-Position
The structure of 2 bound to PA N revealed room for extension at the 5-position into subpocket 4. Compared to 2, a 20-fold improvement in inhibitory activity was seen by adding a 3-benzonitrile at the 5-position (3). Unlike 2, only one molecule of 3 is bound to the active site of PA N , and the benzonitrile group is extended into subpocket 4 ( Figure   4A ). The phenyl ring forms hydrophobic contacts with side chains of Ala24 and Ile38.
Hydrophobic interactions are also seen between the nitrile of 3 and side chains of Lys34
and Ile38. Binding of 3 induces several changes in the active site of PA N compared to the apo structure. Expansion of subpocket 3 occurs due to rearrangements of side chains of Glu26 and Lys34, which now form a new salt bridge ( Figure 4A ). Stabilization of Glu23, which is a part of subpocket 2, was also observed via a hydrogen-bonding interaction with a water molecule that coordinates with M3. Even though M3 is present in the structure, 3 does not directly interact with M3.
The most significant change in the cleft involved Tyr24, a residue that has been structurally shown to be a highly adaptive and involved in nucleotide binding. 18 Compared to the apo structure, binding of 3 caused a ~1 Å backbone shift of Tyr24. A 45º rotation of the side-chain torsion angle χ1 downwards allows the hydroxyl of Tyr24 to chelate to M3, which maintains an octahedral coordination with Tyr24, Glu80, and three surrounding water molecules. Suboptimal weak π interaction between the nitrile moiety of 3 and the aromatic ring of Tyr24 was also observed. 
Substitution at the 6-Position
Relative to 2, a 40-fold increase in inhibitory potency was observed upon addition of a phenyl ring at the 6-position of the pyridinone (4) Substitutions on the phenyl ring of 4 were explored to improve the potency and binding affinity. Of the compounds tested, the strongest electron density was seen for 5, which has a m-methoxyphenyl group at the 6-position of the pyridinone ring ( Figure 4C ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Hydrophobic interactions between the m-methoxyphenyl and side chains of Ala20, Tyr24, and Ile38 were also observed. The IC 50 value of 5 was determined to be 0.45 µM in the enzymatic assay with an LE of 0.54 kcal/(mol·NHA). Although 5 is slightly less active than 4 (0.38 µM), the inhibition by one molecule of 5, which maintained key interactions with all three metal ions as well as residues comprising the active site and subpocket 3 of PA N , was considered to be a remarkable improvement.
Di-substitution at the 5-and 6-Positions
The combination of SAR, molecular docking, and a single, highly superimposable binding mode for the mono-substituted pyridinone ring within the crystal structures indicated that di-substitution at the 5-and 6-positions could be advantageous. This hypothesis was confirmed by a significant improvement in the inhibitory activity seen for the di-substituted compounds compared to 2. Of the di-substituted compounds synthesized and tested, 6, which has a p-fluorophenyl group at both the 5-and the 6-positions, had a 400-fold improvement in inhibitory activity compared to 2. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 hours. As expected, DMSO did not have any effect on viral replication while oseltamivir had an EC 50 value of 0.015 µM, similar to that previously shown for PR8. 50 These results demonstrate the antiviral properties of 7 against a homologous H1N1 subtype virus and the lack of cytotoxicity at the tested concentrations.
Conclusions
Protein engineering was successful in obtaining a high-resolution crystal form of Statistics for data collection and refinement of the X-ray crystal structures are listed in Supplemental Table 5 . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 (7) is shown with yellow carbon atoms and a carboxamide derivative with three chelating groups crystallized by Dubois et al. is shown in gray (PDB code: 4E5I).
19
The subpockets are labeled as previously described.
(B) Superposition of the pH1N1 2009
PA N structures from this study and one previously described (PDB code: 4AVQ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 25 as the positive and negative controls. Cytotoxicity for 7 (shown in red) was determined from MDCK cells after 24 hours using the MTT assay. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 58 59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 58 59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 58 59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 58 59 Figure 5 . Viral yield inhibition assay and cytotoxicity assay. Virus yield assay using MDCK cells and the A/Puerto Rico/8/1934 (H1N1) influenza strain was used to determine the antiviral activity of 7; oseltamivir and 0.1% (v/v) DMSO (only) were used as the positive and negative controls. Cytotoxicity for 7 (shown in red) was determined from MDCK cells after 24 hours using the MTT assay. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
